MAP: XTX101 Monotherapy and/or Combination Therapy in Advanced Solid Tumors - Clinical Trial

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
A Managed Access Protocol for Patients with Advanced Solid Tumors who have Completed Protocol XTX101-01/02-001 (NCT04896697) Monotherapy Vilastobart (XTX101) and/or Combination Therapy Vilastobart and Atezolizumab and Continue to Receive Benefit from Treatment
Principal Investigator
Nicholas C. DeVito, MD
Medical Oncologist
Protocol Number
IRB: PRO00120304
Phase
Phase N/A
Enrollment Status
Open for Enrollment
Support Duke Health research or honor a loved one with a tribute gift.
Giving to Duke Health